The deal values Relievant Medsystems at $850 million, and additional payments are expected over the next three years, according to a Sept. 19 news release.
Intracept is a minimally invasive, implant-free outpatient procedure aimed to address lower back pain. Its efficacy is backed by clinical trials.
The acquisition is explected to close in the first half of 2024.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
